Dr. Bernard Thébaud lives in two very different worlds. As a specialist in the Stollery Children's Hospital's Neonatal Intensive Care Unit at the Royal Alexandra Hospital, he cares for tiny babies, many of whom struggle for breath after being born weeks before they are due.
Across town, in his laboratory in the Faculty of Medicine & Dentistry at the University of Alberta, Dr. Thébaud dons a lab coat and peers into a microscope to examine the precise effect of stem cells on the lungs.
Today, with his scientific research being published in the American Journal of Respiratory and Critical Care Medicine, Dr. Thébaud has made a significant leap to bridge the gap between those two worlds.
An international team of scientists led by Dr. Thébaud has demonstrated for the first time that stem cells protect and repair the lungs of newborn rats. "The really exciting thing that we discovered was that stem cells are like little factories, pumping out healing factors," says Dr. Thébaud, an Alberta Heritage Foundation for Medical Research Clinical Scholar. "That healing liquid seems to boost the power of the healthy lung cells and helps them to repair the lungs."
In this study, Thébaud's team simulated the conditions of prematurity – giving the newborn rats oxygen. The scientists then took stem cells, derived from bone marrow, and injected them into the rats' airways. Two weeks later, the rats treated with stem cells were able to run twice as far, and had better survival rates. When Thébaud's team looked at the lungs, they found the stem cells had repaired the lungs, and prevented further damage.
"I want to congratulate Dr. Thébaud and his team. This research offers real hope for a new treatment for babies with chronic lung disease," says Dr. Roberta Ballard, professor of pediatrics, University of California, San Francisco. "In a few short years, I anticipate we will be able to take these findings and begin clinical trials with premature babies."
"The dilemma we face with these tiny babies is a serious one. When they are born too early, they simply cannot breathe on their own. To save the babies' lives, we put them on a ventilator and give them oxygen, leaving many of them with chronic lung disease," says Dr. Thébaud. "Before the next decade is out I want to put a stop to this devastating disease."
The research team includes physicians and scientists from Edmonton, Alberta, Tours, France, Chicago, Illinois, and Montreal, Quebec.
The team is now investigating the long-term safety of using stem cells as a lung therapy. The scientists are examining rats at 3 months, and 6 months after treatment, studying the lungs, and checking their organs to rule out any risk of cancer. Dr. Thébaud's team is also exploring whether human cord blood is a better option than bone marrow stem cells in treating lung disease.
"We are also studying closely the healing liquid produced by the stem cells," says Dr. Thébaud. "If that liquid can be used on its own to grow and repair the lungs, that might make the injection of stem cells unnecessary."
Dr. Thébaud is a neonatal specialist for Alberta Health Services, and a Canada Research Chair in Translational Lung and Vascular Development Biology. His research is supported by the AHFMR, the Canada Foundation for Innovation, the Canadian Institutes of Health Research, the Canadian Stem Cell Network and the Stollery Children's Hospital Foundation.
The study, Airway Delivery of Mesenchymal Stem Cells prevents Arrested Alveolar Growth In Neonatal Lung Injury In Rats, is available at http://ajrccm.atsjournals.org/current.shtml
Still photos and video content (including a premature baby and her parents) are available for download at www.ahfmr.ab.ca
Media please contact Karen Thomas, AHFMR Media Specialist, 1.877.423.5727 x 225, 1.403.651.1112 (cell), Karen.email@example.com
For more information on this research contact Dr. Bernard Thébaud at firstname.lastname@example.org
Alberta has the highest rate of premature births in Canada with a rate of 9.2% compared to the rest of Canada at 7.8%.
Babies who are born extremely premature – before 28 weeks – cannot breathe on their own. In order to help the babies' lungs to develop, neonatal doctors give them oxygen and drugs to help them breathe.
These treatments contribute to a chronic lung disease known as Bronchopulmonary dysplasia (BPD). At present there is no treatment to heal the lungs of these premature babies.
50% of babies born before 28 weeks will get chronic lung disease. Case studies have shown that as these babies grow up, they continue to struggle with lung disease, coping with reduced lung function and early aging of their lungs.
Karen Thomas | EurekAlert!
Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences